GRB2 and ovarian carcinoma: In ovarian cancer, GRB2 maintains replication fork stability by inhibiting RAD51 ATPase activity, preventing cytosolic DNA release that activates cGAS‐STING; GRB2 deficiency allows PARP inhibitors (PARPis) to induce DNA fragment release and enhance antitumour immunity [52].